From Project Q Atlanta…
Federal health officials warned of new signs that gonorrhea is growing resistant to current treatments, a development more troubling for gay men who face a higher risk of the sexually transmitted disease than other populations.
Findings of a new study from Hawaii prompted the Centers for Disease Control & Prevention to raise a warning flag on Wednesday during its 2016 STD Prevention Conference in downtown Atlanta. The findings showed that the current treatment for gonorrhea – a shot of ceftriaxone and an oral dose of azithromycin – was losing its effectiveness in a cluster of infections in Hawaii.
That’s more troubling than data released in July that showed emerging drug resistance and limited treatment options for gay men at a time when infections among them are on the rise, federal officials said during a press conference Wednesday.
“It seems that in the battle between humans and pathogens, gonorrhea is a formidable opponent,” said Jonathan Mermin (photo), director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD & Tuberculosis Prevention.
“We are seeing troubling signs that treatments are failing us. We may be running out of options for treating gonorrhea,” he added.
Gonorrhea is one of the most common sexually transmitted diseases in the country and it impacts gay men more severely than other populations. The CDC has said about 56 percent of gonorrhea cases in the U.S. are among men and of those, 48 percent are estimated to be gay men. Put another way, men who have sex men face a gonorrhea incidence 17 times greater that seen in heterosexual men and nearly 14 times that seen in women, based on the 2014 STD Surveillance Report.